武汉大学人民医院湖北省人民医院

院内导航

姚颐肿瘤
肿瘤中心总支副书记、肿瘤一科书记兼主任、硕士生导师

A+ A-

导师介绍

姓名	姚颐
出生年月	1980年1月
单位	武汉大学人民医院肿瘤中心
所属学科	临床医学-肿瘤学
职务、职称及头衔	肿瘤中心总支副书记、肿瘤一科书记兼主任、硕士生导师
E-mail	yaoyi2018@whu.edu.cn
联系方式	027-88041911转86505或13545218231
研究方向	1.肿瘤微环境与精准治疗 2. DNA损伤修复与抗肿瘤治疗
个人简介	主要从事肿瘤疾病的诊治与科研、教学工作。获国家自然科学基金资助2项、省科技厅、省教育厅、省卫健委课题5项，其它横向课题10项。参编著作和教材《临床肿瘤规范化诊疗实践与进展——肺癌分册》、《精准肿瘤学解析——进展及案例》。与德、美等国外研究机构联系紧密，在《Cancer Med-US》、《J Pharmacol. Exp. Ther.》、《Front. Immunol.》、《Drug Res Update》、《Genes & Diseases》、《Nat. Commun.》、《The EMBO Journal》、《J. Clin. Oncol.》等杂志上发表论文70余篇，获得计算机软件著作权2项。已参与培养硕士生8名，博士生4名。
学术任职与荣誉	中国抗癌协会（CACA）肺癌专业委员会委员中国抗癌协会（CACA）肿瘤放射治疗专委会肺癌学组委员中国临床肿瘤学会（CSCO）肿瘤生物标志物专委会委员华人放疗协作组（CRTOG）肺癌专委会委员湖北省医学会肿瘤学分会常委湖北省临床肿瘤学会（ESCO）第二届理事会常务理事湖北省临床肿瘤学会（ESCO）肺癌专委会常委湖北省临床肿瘤学会（ESCO）肺癌青年专委会主委湖北省临床肿瘤学会（ESCO）纵隔肿瘤专委会副主委湖北省临床肿瘤学会（ESCO）分子影像专委会常委湖北省临床肿瘤学会（ESCO）食管癌专委会常委湖北省肿瘤专科联盟第一届理事会副理事长湖北省抗癌协会第八届理事会常务理事湖北省抗癌协会肿瘤内科治疗专委会副主委湖北省抗癌协会肿瘤营养与代谢专委会副主委湖北省抗癌协会肺癌专委会常委兼秘书欧洲肿瘤内科学会（ESMO）和美国临床肿瘤学会（ASCO）会员《Frontiers in Genietics》、《Frontiers in Cell and Developmental Biology》客座主编、《中国肿瘤杂志》通讯编委、《国际肿瘤学杂志》编委、《中国肺癌杂志》青年编委
教育履历	1998.09-2003.06武汉大学第一临床学院临床医学专业本科生获学士学位 2003.09-2008.06 武汉大学第一临床学院内科学博士研究生获博士学位
工作履历	2008.07-2008.11 武汉大学人民医院肿瘤中心住院医师 2008.12-2012.11 武汉大学人民医院肿瘤中心主治医师 2012.12-至今武汉大学人民医院肿瘤中心副主任医师 2014.07-2015.09 德国海德堡大学医院、德国癌症研究中心（dkfz）访问学者 2016.08-2016.09 美国得克萨斯医学院MD安德森癌症中心访问学者 2022.09-至今武汉大学人民医院肿瘤一科主任
成果获奖	1、湖北省自然科学优秀学术论文二等奖1项 2、中华医学会医学教育分会教研成果二等奖1项 3、黄石市科技进步二等奖1项 4、武汉大学人民医院“医疗菁英”、“人民抗疫英模”
代表性论著	1、YG Li#, J Chen#, B Wang#, ZW Xu, C Wu, JF Ma, QB Song, Q Geng, JM Yu, HD Pei, Y Yao. FOXK2 affects cancer cell response to chemotherapy by promoting nucleotide de novo synthesis. Drug Resist Update. 2023, 67: 100926. 2、SJ He#, S Zhang#, Y Yao#, et al. Turbulence of Glutamine Metabolism in Pan-cancer Prognosis and Immune Microenvironment. Front Oncol. 2022, 12: 1064127. 3、ZY Zhang#, Y Dong#, B Wu#, YG Li, ZH Liu, ZM Liu, YJ Gao, LK Gao, QB Song, ZL Zheng, Y Yao. Irradiation enhances the malignancy-promoting behaviors of cancer-associated fibroblasts. Front Oncol. 2022, 12: 965660 4、Y Yao, J Zhou, HH Zhang, et al. Identification and validation for biological characteristic and prognosis of tumor microenvironment subtypes in patients with lung adenocarcinoma. J Clin Oncol. 2022, 40(16 suppl): e21006 5、HH Zhang#, Y Yao#, J Wu#, et al. Comprehensive analysis identifies and validates the tumor microenvironment subtypes to predict anti-tumor therapies efficacy in Hepatocellular carcinoma. Front Immunol. 2022; 13: 838374 6、Y Dong#, YG Li#, Y Yao, et al. A novel defined m7G regulator signature to investigate the association between molecular characterization and clinical significance in lung adenocarcinoma. Front Oncol. 2022, 12: 897323. 7、ZM Liu, J Wang, FB Liao, QB Song, Y Yao. Tumor-educated platelets facilitate thrombus formation through migration. Front Oncol. 2022, 12: 857865. 8、SQ Yang#, Y Yao#,, Y Dong, et al. Predict radiation pneumonitis using a genome-scale flux analysis on RNA-seq derived from peripheral blood. Front Med. 2021, 8: 715961 9、B Xu#, KH Song#, Y Yao#, et al. Individualized model for predicting COVID-19 deterioration in patients with cancer: A multicenter retrospective study. Cancer Sci. 2021, 112(6): 2522-2532. 10、Y Yao#, YX Chu#, B Xu, et al. Risk factors for distant metastasis of patients with primary triple-negative breast cancer. Biosci Rep. 2019, 39(6): BSR20190288. 11、SF Ye#, XF Chen#, Y Yao#,, et al. Thioredoxin Reductase as a Novel and Efficient Plasma Biomarker for the Detection of Non-Small Cell Lung Cancer: a Large-scale, Multicenter study. Sci Rep. 2019, 9(1): 2652 12、Y Yao#, YX Chu#, B Xu, et al. Radiotherapy after surgery has significant survival benefits for patients with triple negative breast cancer. Cancer Med. 2019, 8(2): 554-563. 13、Y Yao#,, M Peng#, QL Shen#, et al. Detecting EGFR Mutations and ALK/ROS1 Rearrangements in Non-Small Cell Lung Cancer Using Malignant Pleural Effusion Samples. Thorac Cancer. 2019, 10(2): 193-202 14、Zhang C#, Zeng WF#, Yao Yi#, et al. Naringenin ameliorates radiation-induced lung injury by lowering IL-1β level. J Pharmacol Exp Ther. 2018, 366(2): 341-348. 15、Yao Y#,, Zheng ZL, Song QB. Mesenchymal stem cells: a double-edged sword in radiation-induced lung injury. Thorac Cancer. 2018, 9(2): 208-217.

Name	YI YAO
Date of birth	Jan, 1980
Department	Cancer Center, Renmin Hospital, Wuhan University.
Title	Director, Associate Chief Physician, Master Tutor
Email	yaoyi2018@whu.edu.cn
TEL	027-88041911 ext 86505 or 13545218231
Research Direction	1. Tumor microenvironment and precision therapy 2. Relationship between DNA damage repair and antitumor therapy
Personal Profile	His team is mainly engaged in the treatment and scientific research of cancer. His points of interest is to investigate the effect of irradiation on the tumor immune microenvironment (TIME) and the underlying mechanism, and to optimize the strategy of tumor radiotherapy based on their findings. His research has been supported by two items of the National Natural Science Foundation of China, five of Natural Science Foundation projects of Hubei Province, one of Higher Education Reform Project of Hubei Province and ten horizontal projects as well. He has participated in the editing of “Practice and Progress in Standardized Diagnosis and Treatment of Clinical Oncology (Lung Cancer Volume)” and “Accurate Oncology Analysis -- Progress and Cases”. His team maintains close scientific research cooperation with foreign research institutions, such as the National Cancer Research Center of Germany (DKFZ), Heidelberg University (Germany), the University of Bonn (Germany), MD Anderson Cancer Center of Texas Medical School (USA), Georgetown University (USA). His team have published more than 130 papers in top magazines such as Cancer Medicine, Genes & Diseases, Journal of Pharmacology and Experimental Therapeutics, Nature Communication, Nature biochemical biology, the EMBO Journal, Journal of Clinical Oncology, Drug Resistance Update, Frontiers in Immunology, Frontiers in Oncology, Thoracic Cancer and Urology. More than half of them were published by himself as the first author or corresponding author. Nevertheless, he has obtained two computer software copyrights. Eight master students and four doctoral students are being under his training.
Selected Publications	1、YG Li#, J Chen#, B Wang#, ZW Xu, C Wu, JF Ma, QB Song, Q Geng, JM Yu, HD Pei, Y Yao. FOXK2 affects cancer cell response to chemotherapy by promoting nucleotide de novo synthesis. Drug Resist Update. 2023, 67: 100926. 2、SJ He#, S Zhang#, Y Yao#, et al. Turbulence of Glutamine Metabolism in Pan-cancer Prognosis and Immune Microenvironment. Front Oncol. 2022, 12: 1064127. 3、ZY Zhang#, Y Dong#, B Wu#, YG Li, ZH Liu, ZM Liu, YJ Gao, LK Gao, QB Song, ZL Zheng, Y Yao. Irradiation enhances the malignancy-promoting behaviors of cancer-associated fibroblasts. Front Oncol. 2022, 12: 965660 4、Y Yao, J Zhou, HH Zhang, et al. Identification and validation for biological characteristic and prognosis of tumor microenvironment subtypes in patients with lung adenocarcinoma. J Clin Oncol. 2022, 40(16 suppl): e21006 5、HH Zhang#, Y Yao#, J Wu#, et al. Comprehensive analysis identifies and validates the tumor microenvironment subtypes to predict anti-tumor therapies efficacy in Hepatocellular carcinoma. Front Immunol. 2022; 13: 838374 6、Y Dong#, YG Li#, Y Yao, et al. A novel defined m7G regulator signature to investigate the association between molecular characterization and clinical significance in lung adenocarcinoma. Front Oncol. 2022, 12: 897323. 7、ZM Liu, J Wang, FB Liao, QB Song, Y Yao. Tumor-educated platelets facilitate thrombus formation through migration. Front Oncol. 2022, 12: 857865. 8、SQ Yang#, Y Yao#,, Y Dong, et al. Predict radiation pneumonitis using a genome-scale flux analysis on RNA-seq derived from peripheral blood. Front Med. 2021, 8: 715961 9、B Xu#, KH Song#, Y Yao#, et al. Individualized model for predicting COVID-19 deterioration in patients with cancer: A multicenter retrospective study. Cancer Sci. 2021, 112(6): 2522-2532. 10、Y Yao#, YX Chu#, B Xu, et al. Risk factors for distant metastasis of patients with primary triple-negative breast cancer. Biosci Rep. 2019, 39(6): BSR20190288. 11、SF Ye#, XF Chen#, Y Yao#,, et al. Thioredoxin Reductase as a Novel and Efficient Plasma Biomarker for the Detection of Non-Small Cell Lung Cancer: a Large-scale, Multicenter study. Sci Rep. 2019, 9(1): 2652 12、Y Yao#, YX Chu#, B Xu, et al. Radiotherapy after surgery has significant survival benefits for patients with triple negative breast cancer. Cancer Med. 2019, 8(2): 554-563. 13、Y Yao#,, M Peng#, QL Shen#, et al. Detecting EGFR Mutations and ALK/ROS1 Rearrangements in Non-Small Cell Lung Cancer Using Malignant Pleural Effusion Samples. Thorac Cancer. 2019, 10(2): 193-202 14、Zhang C#, Zeng WF#, Yao Yi#, et al. Naringenin ameliorates radiation-induced lung injury by lowering IL-1β level. J Pharmacol Exp Ther. 2018, 366(2): 341-348. 15、Yao Y#,, Zheng ZL, Song QB. Mesenchymal stem cells: a double-edged sword in radiation-induced lung injury. Thorac Cancer. 2018, 9(2): 208-217.